Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 301 first-line sotorasib + panitumumab + FOLFIRI vs FOLFIRI ± bevacizumab in KRAS p.G12C metastatic colorectal cancer
jRCT2071240009Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sotorasib in metastatic colon cancer (mCRC), colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival (PFS) per RECIST v1.1. Started Jul 2024; status: recruiting.
02
Drugs
sotorasib
03
Conditions
metastatic colon cancer (mCRC)colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2071240009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240009.